Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events

BACKGROUND: Increased rates of respiratory adverse events have been observed in people ≥12 years of age with cystic fibrosis homozygous for the Phe508del-CFTR mutation treated with lumacaftor/ivacaftor, particularly in those with percent predicted forced expiratory volume in 1 s (ppFEV(1)) of <40...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwarz, Carsten, Sutharsan, Sivagurunathan, Epaud, Ralph, Klingsberg, Ross C., Fischer, Rainald, Rowe, Steven M., Audhya, Paul K., Ahluwalia, Neil, You, Xiaojun, Ferro, Thomas J., Duncan, Margaret E., Bruinsma, Bote G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187869/
https://www.ncbi.nlm.nih.gov/pubmed/32586736
http://dx.doi.org/10.1016/j.jcf.2020.06.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187869/
https://www.ncbi.nlm.nih.gov/pubmed/32586736
http://dx.doi.org/10.1016/j.jcf.2020.06.001

Ejemplares similares